Cellular hypoxia response is regulated at the level of hypoxia-inducible factor (HIF) activity. A number of recently identified oxygen sensors are HIF-modifying enzymes that respond to low oxygen by altering HIF modification and thus lead to its activation. In addition to the HIF proline hydroxylases and asparagine hydroxylases, ARD1 is recently described as a HIF-1␣ acetylase that regulates its stability. We found that ARD1 is downregulated in a number of cell lines in response to hypoxia and hypoxia mimic compounds. After surveying these lines for erythropoietin production and retroviral transfection efficiency, we chose to use HepG2 cells to study the function of ARD1. ARD1 short hairpin RNA delivered by a retroviral vector caused >80% reduction in ARD1 message. We observed decreases in erythropoietin and vascular endothelial growth factor protein production, whereas there was no change in the HIF-1␣ protein level. A gene chip analysis of HepG2 cells transduced with virus expressing ARD1 short hairpin RNA under normoxia and hypoxia conditions or with virus overexpressing recombinant ARD1 confirmed that inhibition of ARD1 does not cause activation of HIF and downstream target genes. However, this analysis revealed that ARD1 is involved in cell proliferation and in regulating a series of cellular metabolic pathways that are regulated during hypoxia response. The role of ARD1 in cell proliferation is confirmed using fluorescence labeling analysis of cell division. From these studies we conclude that ARD1 is not required to suppress HIF but is required to maintain cell proliferation in mammalian cells.
tissue utilization of oxygen and nutrients under a low oxygen environment. These events are known to be coordinated by a key transcription factor complex: HIF-1 (2, 3), which is activated by hypoxia and stimulates the transcription of hypoxiaresponsive genes.
HIF-1 is composed of two subunits: the hypoxia-regulated subunit, HIF-1, and the oxygen-insensitive HIF-1 subunit (4) . Under normoxia, the HIF-1 subunit is rapidly degraded via the von Hippel-Lindau tumor suppressor gene product (pVHL)-mediated ubiquitin-proteasome pathway (5) (6) (7) (8) . The association of pVHL and HIF-1 under normoxic conditions is triggered by the posttranslational hydroxylation of several prolines within a polypeptide segment known as the oxygen-dependent degradation domain (9 -11) through the function of specific HIF-prolyl hydroxylases (12) (13) (14) . The hydroxylation of an asparagine in the C-terminal transactivation domain of HIF-1 inhibits interaction with the p300/CBP (CREB-binding protein) coactivator and reduces the transcriptional activity of HIF-1 during normoxic conditions (15) (16) (17) .
A recent study reported ARD1 as a protein acetyltransferase in mammalian cells and that the acetylation of HIF-1 by ARD1 regulates the stability of HIF-1 in response to O 2 concentration (18) . To further investigate the role of ARD1 in hypoxia, we examined cellular function during normoxia and hypoxia upon inhibition and overexpression of ARD1.
MATERIALS AND METHODS
Western Blotting and ELISA-3 ϫ 10e6 cell aliquots were treated with 15 M FG2229 or Me 2 SO in low serum medium over a 3-h time course. The cells were collected at various time points, washed with cold phosphate-buffered saline, and lysed with a NE-PER nuclear and cytoplasmic extraction kit (Pierce). Nuclear extracts were prepared, and 20 g of total protein samples were run on a 4 -20% SDS-PAGE. The gel was transferred to nitrocellulose and blocked for 1 h at room temperature with 1ϫ Western blocking buffer (Roche Applied Science). The blot was probed with anti-HIF1 ␣ (BD Pharmingen) plus peroxidase-labeled anti-mouse Ig. ARD1 Western blotting was done with a chicken antihuman ARD1 polyclonal antibody from Genway Biotech. The blot was developed with Pierce West-Pico substrate and visualized with a Roche Applied Science Lumi-Imager work station.
Real Time PCR-Custom primer sets were designed according to default design parameters for TaqMan primer/probe set design using Applied Biosystems Primer Express 2.0 software. The following forward and reverse primer sets were synthesized: human EGLN1 (Egl-Nine; accession number AF229245), forward, AATGGCCGGACGAAAGC, and reverse, TTTGGATTATCAACATGACGTACATAAC; human EGLN2 (accession number BC001723), forward, CCTGAATCAGAACT-GGGACGTT, and reverse, CGGCCCTCAGGGAAGATC; human EGLN3 (accession number XM_012332), forward, CGAAGTGCAGC-CCTCTTACG, and reverse, CTTTTTGGCTTCTGCCCTTTC; human ARD1 (accession number NM_003491), forward, GGCCCCAGCTCTCT-TACATTG, and reverse, TTCCATTTTGGCCAGGACAT; human erythropoietin (accession number NM_000799), forward, AGCCCAGAAG-GAAGCCATCT, and reverse, GGAAAGTGTCAGCAGTGATTGTTC; and human glyceraldehyde-3-phosphate dehydrogenase (accession number NM_002046), forward, GAAGGTGAAGGTCGGAGTC, and re-* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
verse, GAAGATGGTGATGGGATTTC. Real time assays were performed by SYBR green incorporation in triplicate 25-l reactions with 100 nM primers plus 12.5 ng of cDNA template using Bio-Rad iQ-SYBR Supermix and real time data collection on the Bio-Rad iCycler. Melt curve analysis for all of the primer sets was performed to confirm the presence of a single product and the absence of primer-dimer. Relative gene expression was determined by ⌬⌬C t calculation utilizing glyceraldehyde-3-phosphate dehydrogenase as the normalizer.
shRNA-Six separate hairpin sequences were analyzed for reduction of human ARD1 gene expression by HepG2 cells (data not shown). The sequences were selected using the Cold Spring Harbor hairpin sequence design algorithm found at www.cshl.org/public/SCIENCE/hannon.html and inserted to the retroviral hairpin expression vector pMH1_Kk for retroviral delivery. Two of the six target sequences were effective for gene knockdown as determined by real time PCR: ARD1.3 (5Ј-CCCTG-CACCTCTATTCCAACACCCTCAA) and ARD1.6 (5Ј-ATGCAGCACT-GCAACCTCCTCTGCCTGC).
Retrovirus Production and Transduction-293 cells were plated and grown overnight to 50 -60% confluency in T-75 flasks. The cells were cotransfected with 4 g of amphotrophic retroviral packaging vector pCL_10A1 (Imgenex) and 4 g of hairpin expression transfer vector pMH1_Kk using FuGENE 6 transfection reagent (Roche Applied Science). Following an overnight incubation the medium was then changed to fresh low serum media UltraCulture (Cambrex) and allowed to incubate an additional 24 h prior to harvest of the viral supernatants. Roughly 100,000 HepG2 cells in 1 ml of medium were plated per well in 12-well plates and incubated 2-3 h prior to the addition of 0.3 ml of viral supernatants plus polybrene to 5 g/ml. The plates were centrifuged at 2000 rpm for 1 h at room temperature and placed in a 37°C incubator overnight. The following day the medium was aspirated away, replaced with a second aliquot of diluted virus plus polybrene, and centrifuged as described. Following overnight incubation the medium was changed and continued to incubate another 24-h period prior to analysis. The cell samples were analyzed for mouse H-2Kk surface marker expression by FACS to confirm transduction and RNA samples collected for real time PCR analysis and Affymetrix profiling. Hypoxia samples were generated by incubation of the plate in a Billups-Rothenberg modular incubator chamber flushed with 95% nitrogen, 5% carbon dioxide.
CFSE Proliferation Analysis-Two days following retroviral transduction, HepG2 cells treated with control, ARD1.3, and ARD1.6 viruses were treated overnight with 600 nM nocodazole. The cell samples were collected and stained with 20 M CFSE stain in phosphate-buffered saline with 0.1% bovine serum albumin for 10 min at 37°C. Following incubation, cold Dulbecco's modified Eagle's medium was added, and the samples incubated on ice 5 min. The samples were then washed with complete mediaum and plated to triplicate wells of a 12-well tissue culture plate. On days 1, 3, and 7 post-CFSE stain, the cells were collected and stained with biotinylated anti-H-2Kk plus streptavidin-APC. CFSE and APC staining were analyzed by FACS using a BD FACS Calibur and Cellquest software.
Gene Chip-Total RNA was processed using an internally developed protocol that incorporated variations of Hunter's amplification and Affymetrix protocol (19) . The modifications made to the protocols allow a 25-40-fold increase in cRNA versus input RNA with one round of amplification. 500 ng of total RNA was converted to double stranded cDNA using a T7-(dT) 24 oligonucleotide primer (Genset) with a cDNA superscript kit (Invitrogen) supplemented with T4gp32 (USB Corporation) and RNA Guard ribonuclease inhibitor (Amersham Biosciences). Double-stranded cDNA was purified using 0.5 ml of Phase lock Gel I-light 5Ј-3Ј Prime (Eppendorf). In vitro biotin-labeled cRNA transcription was carried out using the BioArray high yield RNA transcript labeling kit (Enzo Diagnostics), and the reactions were incubated at 37°C for 16 h. Biotin-labeled cRNA was purified using RNeasy spin columns from Qiagen. cRNA yields ranged from 15 to 30 g. 15 g of biotinylated cRNA was fragmented by heating at 94°C for 35 min in the presence of fragmentation buffer. 10 g of fragmented cRNA were hybridized to the Human Genome U133a arrays at 45 C for 16 h. The Human Genome U133a array represents 14,500 human genes and covers more than 22,000 probe sets. The arrays were washed and stained with the Affymetrix automated Genechip Fluidics station with fluidics protocol EukGE-WS2 and then scanned with the GeneArray Scanner.
Statistical Analysis of Gene Chip Data-Gene expression levels were obtained from the gene chip data using the Affymetrix GCOS algorithm. The data were scaled to a target intensity of 300 and a minimum intensity of 20 used in the calculation of fold change. In parallel, the data were obtained directly from the .cel files and normalized using the Irizarry robust multi-array method (20) . After normalization, a simple one-way analysis was used to identify those probe sets that had a significant treatment effect. The Benjamini-Hochberg false discovery rate method was used to correct for multiple comparisons or t tests (20) . Probe sets that showed significant treatment effects were evaluated for response to hypoxia and ARD1 modulation and tested to identify those that responded in defined patterns to the treatments applied in this study: pattern 1, change from Normoxia-Kk to Hypoxia Kk and from Normoxia-Kk to Normoxia ARD1.3; pattern 2, change from Normoxia-Kk to Hypoxia-Kk and from Normoxia Kk to Normoxia ARD1.6; pattern 3, change from Normoxia-Kk to Normoxia Ard1.6 and Normoxia Kk to Normoxia ARD1.3; pattern 4, interaction between culture conditions (Normoxia, Hypoxia) and ARD1 expression level; and pattern 5, change from Normoxia ARD1.3-Kk opposite to Normoxia Flag ARD1.3-Kk. To analyze which genes in Normoxia with ARD1 knockdown resemble hypoxia, the following method was used. The probe sets that were statistically different in each of the following contrasts were identified: contrasts A, change from Kk-normoxia to Kk-hypoxia and change from Kk-normoxia to 1.3-normoxia; contrasts B, change from Kk-normoxia to Kk-hypoxia and change from Kk-normoxia to 1.6-normoxia; and contrasts C, change from Kk-hypoxia to 1.6-hypoxia and change from Kk-normoxia to 1.3-normoxia. The probe sets that had a significant treatment effect were identified using the following model: log2(Intensity) ϭ Overall Mean ϩ Treatment, where Treatment is a factor with six levels (the six samples). The fold changes reported were obtained using the MAS 5.0, whereas all other analysis was based on using robust multi-array normalized data. The data were visualized using the Spotfire Decision Site for Functional Genomics.
Functional Analysis of Gene Chip Data-Functional analysis of the gene chip data were completed through the use of Ingenuity Pathways Analysis, a web-delivered application that enables biologists to discover, visualize, and explore therapeutically relevant networks significant to their experimental results. For a detailed description of ingenuity pathways analysis, visit www.ingenuity.com. A file containing the Affymetrix identifiers of those genes that passed the statistical analysis, corresponding fold changes, and p values was uploaded into the ingenuity pathway analysis tool. Each gene identifier was mapped to its corresponding gene object in the ingenuity pathways knowledge base. A fold change cutoff of 1.5 was set to identify genes whose expression was significantly differentially regulated. These genes, called focus genes, were then used as the starting point for generating biological networks. To start building networks, the application queries the ingenuity pathways knowledge base for interactions between focus genes and all other gene objects stored in the knowledge base and generates a set of networks with a network size of 35 genes/proteins. Ingenuity pathways analysis then computes a score for each network according to the fit of the user's set of significant genes. The score is derived from a p value and indicates the likelihood of the focus genes in a network being found together because of random chance. The functional information associated with the genes was taken from Gene Ontology (21) and LocusLink.
RESULTS

Erythropoietin Production in Response to Hypoxia Mimic
Conditions-Erythropoietin is a major HIF target gene expressed in response to hypoxia. Kidney is the major site of erythropoietin production in vivo, and liver cells are also known to produce some erythropoietin (22) . Kidney cells that produce erythropoietin have not been isolated so far, whereas a number of liver cell lines, including HepG2 and Hep3B are known to produce erythropoietin (23) . In addition, human hematopoietic progenitor cells are reported to produce modest amount of erythropoietin (24) . We first examined a number of cell lines for their ability to express erythropoietin in response to CoCl 2 , a hypoxia mimic compound, and FG2229, a known proline hydroxylase inhibitor that was shown to inhibit the HIF proline hydroxylase EGLN1/PHD2/HPH2 (13) . Stabilization of HIF is a ubiquitous response to hypoxia mimic treatment. FG2229 caused HIF1␣ accumulation in the nuclei within an hour of treatment (Fig. 1A) . The level of HIF1␣ protein plateaued within 2 h of FG2229 treatment. Among the cell lines examined, Hep3B cells are known to produce the highest amount of erythropoietin. As expected, we observed a 10-fold increase in erythropoietin production in Hep3B cells (Fig. 1B) upon FG2229 treatment and a 2-fold increase in erythropoietin production in HepG2 cells (Fig. 1C) . No erythropoietin produc-tion was observed in K562 and 293T cells, although a modest amount of erythropoietin mRNA was detected in K562 cells (data not shown). We next examined the expression of VEGF, which is known to be produced in a broader range of cells, in 293T cells and HepG2 cells and found high level expression induced by FG2229 in both cell lines (Fig. 1D) .
In addition to erythropoietin and VEGF, HIF-modifying enzymes including proline hydroxylases EGLN1/PHD2/HPH2, EGLN2/PHD1/HPH3, EGLN3/PHD1/HPH3 (12) , and ARD1 (18) are all known to be regulated by hypoxia. EGLN1/PHD2/ HPH2 and EGLN3/PHD1/HPH3 expression were increased upon the treatment with prolyl hydroxylase inhibitor or CoCl 2 ( Fig. 2) , as previously reported, except in 293T cells (Fig. 2D) , where EGLN3/PHD1/HPH3 expression is decreased. Unlike reported in HeLa cells (12, 25) , treatment of HepG2, Hep3B, K562, and 293 cells all caused decreased expression of EGLN2/ PHD1/HPH3. These observations indicated cell type-specific differences in target gene activation during hypoxia responses and suggested that qualitative differences in HIF modification might contribute to this outcome.
The expression of ARD1 in these cell lines decreased upon hypoxia mimic treatment as previously reported in HT1080 cells (18) . A BLAST search of GenBank TM using ARD1 DNA sequence identified a novel gene with 81% amino acid identity with ARD1, which we named ARD2 (MGC10646). We found ARD2 is expressed in K562 cells but not in 293T and HepG2 (Fig. 2B) .
ARD1 RNA Interference-We next used RNA interference technology to examine the function of ARD1 in hypoxia response. We selected six 29-bp sequences from human ARD1 cDNA to target with RNAi. DNA oligonucleotides encompassing these sequences were cloned into a retroviral RNAi vector that allows the expression of a hairpin RNAi molecule. Recombinant virus harboring these RNAi vectors were generated and used to infect cell lines. In one version of the vector, green fluorescent protein was coexpressed in a bi-cistronic expression cassette. A FACS analysis of cells infected with the virus showed that Ͼ95% of 293T cells and HepG2 cells are green fluorescent protein positive (data not shown). Among the six sets of RNAi vectors, two produced significant ARD1 mRNA (Fig. 3A) and protein (Fig. 3B) knockdown: hairpin 1.3 knocked down ARD1 85%, and hairpin 1.6 knocked down ARD1 35%, whereas control Kk virus alone does not cause significant changes in expression level. A time course analysis of ARD1 mRNA knockdown showed that 72 h post-infection is required to reach optimal ARD1 mRNA inhibition. This knockdown lasted throughout the observation period up to 2 weeks (data not shown).
A second version of the viral RNAi vector expresses a truncated version of the Kk molecule instead of green fluorescent protein in the bi-cistronic cassette. This allows for surface expression of the Kk molecule on cells infected with the recombinant virus. This feature allowed for the enrichment of Hep3B cells that are poorly infected by retrovirus. However, the slow growth nature of Hep3B cells made downstream assays problematic. We thus used HepG2 cells in most of the analyses that follow. When examining erythropoietin and VEGF protein levels in cells treated with ARD1 viral RNAi, we found that, surprisingly, these cells produced significantly lower amounts of erythropoietin and VEGF (Fig. 3, C and D) . Western blotting of HIF1␣ showed that inhibition of ARD1 in HepG2 cells and 293T cells does not cause any changes in HIF1␣ protein level under normoxia (data not shown), whereas it is stabilized under hypoxia condition. To verify these findings and, more importantly, to obtain insights into the cellular pathways regulated by ARD1 in the context of hypoxia response, we performed gene expression profiling analysis of ARD1 knock- 
ARD1 Inhibition Does Not Affect the Expression of Erythropoietin and VEGF-Seven sets of HepG2 samples in triplicate
were prepared for Affymetrix chip analysis. Six of these samples were transduced with virus expressing the following constructs under the indicated conditions: 1) Kk under normoxia condition (Kk-normoxia), 2) Kk1.3 hairpin under normoxia condition (1.3-normoxia), 3) Kk1.6 hairpin under normoxia condition (1.6-normoxia), 4) Kk under hypoxia condition (Kk-hypoxia), 5) Kk1.3 hairpin under hypoxia condition (1.3-hypoxia), and 6) Kk1.6 hairpin under hypoxia condition (1.6-hypoxia). The last sample is HepG2 cells overexpressing ARD1 with the Kk viral vector under normoxia condition (ARD1-Kk). The ARD1 expression levels in all seven sets of the total 21 samples are as expected (Fig. 4) . Analysis of the ARD1 expression level using quantitative reverse transcription-PCR in these samples confirmed the desired changes in ARD1 mRNA. Under both normoxia and hypoxia conditions, hairpin 1.3 knocked down ARD1 by 85%, and hairpin 1.6 knocked down ARD1 by 35%. Upon overexpression of ARD1, the ARD1 mRNA level reached 4.5-fold of Kk control level. The Affymetrix mouse U133A chip was used for gene expression profile analysis. The results reported in this figure are based on genes that showed a statistically significant (p Ͻ 0.05) increase of 2-fold or more in the expression level.
The level of knockdown of ARD1 by hairpins 1.3 and 1.6 analyzed by the gene chip agrees very well with the quantitative PCR data (Fig. 5) . We first examined the expression level of hypoxia related genes in these samples. Although VEGF, erythropoietin, EGLN3/PHD1/HPH3, and EGLN1/PHD2/ HPH2 are significantly induced in all hypoxia-treated samples, no changes in these genes were observed in the samples treated with hairpins 1.3 and 1.6. For the group of hypoxia-related genes shown in Fig. 5 , the combination of ARD1 knockdown and hypoxia treatment only led to additive changes; no synergistic changes were seen. To confirm the gene chip data, we performed reverse transcription-PCR analysis of erythropoietin and VEGF mRNA and obtained essentially the same result as that obtained from using the gene chip. As noted above, ARD2 was expressed at extremely low level in HepG2 cells, nevertheless detectable by the gene chip. The expression of ARD2 showed no signs of compensatory expression upon ARD1 inhibition. Thus, we conclude that ARD1 is not required for maintaining the normoxia state of HIF protein and target gene expression as has been shown for EGLN1/PHD2/HPH2. In other words, ARD1 is not required for the suppression of HIF.
ARD1 Inhibition Causes Changes in Genes Involved in
Multiple Pathways-Hypoxia-treated samples showed increased expression of hypoxia response genes and decreased expression of a number of characteristic metabolic enzymes (Table I) . Among the 10 genes that are most dramatically inhibited by the hairpin 1.3 are genes involved in cell growth and survival, for example, beclin 1 (a coiled-coil, myosin-like BCL2-interacting protein), which protects against apoptosis, and tumor protein D52, which is a marker of cell proliferation (26) . A second group of genes strongly suppressed in ARD1 RNAi-treated samples are genes involved in metabolism: glycerol kinase, the thioltransferase glutaredoxin, and N-acetylglucosamine-phosphate mutase, for example.
Among the 10 most highly up-regulated genes in the 1.3-normoxia samples, a prominent group of extracellular matrix genes are up-regulated. These include type II collagen ␣, type IV collagen ␣ 5, fibrillin 1, and galectin 7 (LGALS7). These proteins could be involved in cell-cell and/or cell interactions necessary for normal growth regulation by ARD1. Alternatively, these could reflect a more general extracellular matrix modulatory effect of ARD1. In addition, among the 10 most highly up-regulated genes in the 1.3-normoxia samples, BIK is involved in negative regulation of cell growth. This agrees well with the down-regulation of proliferation promoting genes mentioned above. Thus, inhibition of ARD1 by RNAi appears to correlate with the inhibition of genes involved in cell proliferation and with the up-regulation of anti-proliferative genes.
Common Genes Regulated by Hypoxia and ARD1-Genes regulating metabolism and cell growth are the major groups of genes that have been modulated in the 1.3-normoxia samples. Because hypoxia is also known to modulate expression of genes involved in metabolism and growth regulation, we then investigated whether there are any similarities between ARD1 knockdown samples and hypoxia-treated samples. We ana- -regulated and down-regulated genes in 1.3-normoxia, 1.6-normoxia, lyzed genes that show the same trend of expression between 1.3-normoxia and Kk-hypoxia. There were 5128 probe sets that had a significant treatment effect compared with the Kk only sample. For each probe set, the contrast between changes from Kk-normoxia to Kk-hypoxia and changes from Kk-normoxia to 1.3-normoxia was analyzed. 65 genes are up-regulated and 148 genes are down-regulated in both 1.3-normoxia and Kk-hypoxia samples. Among these genes, the genes involved in metabolism and growth regulation are again the major groups. It is obvious from Table I that the weak inhibition of ARD1 by the 1.6 hairpin only generated modest perturbation of gene expression. And it is not surprising that 1.3-normaxia and 1.6-normaxia shared only four commonly regulated genes; glucose transporter 3 is commonly up-regulated, and ARD1, human RAD51, and ICT1 (immature colon carcinoma transcript 1) are commonly down-regulated. Human RAD51 is a p53-dependent DNA recombinase involved in DNA repair (27, 28) . ICT1 is associated with neoplasia and is down-regulated upon cell differentiation (29) .
Although the 1.3-normoxia and Kk-hypoxia samples share a large group of commonly regulated genes, the 1.6-normoxia and Kk-hypoxia samples only have nine genes commonly regulated: two down-regulated and seven up-regulated (Table II) . The names and fold changes of genes in this table are listed in the supplemental material. Comparing 1.3-normoxia, 1.6-normoxia, and Kk-hypoxia samples together, one gene is up-regulated in all three samples, and two genes are down-regulated in all three samples. One of these commonly down-regulated genes is ARD1 itself; the other one is RAD51. The commonly up-regulated gene is glucose transporter 3. Thus, the overlap between ARD1-regulated genes and hypoxia-regulated genes includes genes involved in energy metabolism and growth regulation.
ARD1 Is Involved in Cell Proliferation-To further define the function of ARD1, we examined gene expression profiles of Hep2 cell overexpressing ARD1. Overexpression of ARD1 resulted in a 4.5-fold increase in ARD1 message. The expression levels of 39 genes were increased, and the expression levels of 32 genes were decreased. The increases in expression are all less than 70%. Three genes were identified that were induced by ARD1 overexpression while inhibited by ARD1.3 RNAi (Table III). The names and fold changes of genes affected by ARD1 RNAi and overexpression are listed in the supplemental material. These are cell division control protein 2, complement component 8␥, and adriamycin sensitivity protein (a seven transmembrane-domain protein). The activation of cell division control protein 2 by ARD1 is in agreement with the above analysis that showed regulation of genes involved in cell growth by ARD1, suggesting a pro-cell growth and proliferation role of ARD1. To directly test this, we examined proliferation of HepG2 cells transduced with retrovirus expressing ARD1 RNAi. We labeled cells with CFSE to track cell division (Fig. 6) . At day 1 post labeling, the cell division appears similar among Kk control, 1.3 RNAi group, and 1.6 RNAi group. At 3 days post labeling, cell division in the 1.3 and 1.6 groups started to slow down compared with Kk control. At 7 days post labeling, the cells treated with ARD1 RNAi showed dramatic reduction in cell division with the 1.3 hairpin, showing a more pronounced effect than the 1.6 hairpin. The x-mean fluorescence intensity at day 7 is 11.92 for the Kk group, 24.77 for the 1.6 RNAitreated sample, and 29.54 for the 1.3 RNAi-treated samples. This result confirmed the role of ARD1 in maintaining cell proliferation. DISCUSSION A number of HIF-modifying enzymes have recently emerged as important oxygen sensors and regulators of hypoxia response. The expression of the proline hydroxylases EGLN1/ PHD2/HPH2, EGLN2/PHD1/HPH3, and EGLN3/PHD1/HPH3 are differentially regulated during hypoxia response, contributing to feedback regulation and recovery from hypoxia reaction. These genes can serve as useful markers of hypoxia response. We found that different cell lines show very different profiles of proline hydroxylase expression. These might reflect different HIF modification in different cell lines, which may be contributing to the unique spectrum of hypoxia response genes induced in each line.
ARD1 is recently reported as a HIF acetylase (18) , and inhi- bition of ARD1 using antisense oligonucleotide or mutation of the putative ARD1 modified lysine residue in HIF-1 ␣ was shown to be sufficient to stabilize HIF-1 ␣ protein. To evaluate the role of ARD1 in downstream target gene expression upon HIF activation, we examined the effect of ARD1 inhibition on erythropoietin and VEGF expression in a number of cell lines. To our surprise, we did not observe any increase in HIF protein level upon inhibition of ARD1 using RNAi in both 293T cells and HepG2 cells. We also looked into the possibility of compensation upon ARD1 inhibition. Yet no compensatory expression of a close homolog of ARD1 was seen.
ARD1 is required for the expression of protein N-acetyltransferase activity in lower eukaryotes and bacteria (30, 31) . However, its function in mammalian cells has not been defined. Gene chip analysis of ARD1 RNAi-treated cells revealed that genes involved in cell proliferation and energy metabolism are influenced by ARD1. Reduced cell proliferation was observed in ARD1 shRNA-treated cells, confirming the gene chip observation of increased expression of anti-proliferation genes and decreased expression of proliferation promoting genes. Although no HIF stabilization was seen upon the inhibition of ARD1, we nonetheless observed an intriguing decrease of erythropoietin and VEGF protein level in the supernatant. The reduced cell proliferation in ARD1 RNAi-treated HepG2 cells is likely responsible for lowered production of erythropoietin and VEGF. No mRNA changes in erythropoietin and VEGF were observed in gene chip and reverse transcription-PCR analysis, which are normalized based on the quantity of mRNA or a control gene.
Analysis of gene expression profiles of cells treated with ARD1 RNAi and ARD1 overexpression revealed regulation of cell proliferation as a potential function of ARD1. A number of genes involved in cell proliferation and metabolic control are commonly regulated by ARD1 inhibition and hypoxia. Human RAD51 is one example. Hypoxia-induced reduction in RAD51 homolog may be a relaxation of the DNA monitor/repair process caused by reactive oxygen species. ARD1 RNAi and hypoxia both stimulated the expression GLUT3. High GLUT3 protein expression is confined generally to tissues that exhibit a high glucose demand, such as brain and nerve (32) . Change in glucose uptake and utilization is a hallmark of hypoxia response. The fact that ARD1 also regulates genes involved in this pathway raises interesting questions as to whether ARD1 mediates certain hypoxia responses, although inhibition of ARD1 alone is not sufficient to stabilize HIF. Whether these cellular responses during hypoxia are directly mediated by ARD1 awaits further investigation.
